|
|
|
Volumn 8, Issue 5, 2007, Pages 362-363
|
|
Editorial overview: A balancing act - Making the right choices in anti-inflammatory drug development
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIINFLAMMATORY AGENT;
BETA1A INTERFERON;
CDP 323;
GLATIRAMER;
INTERFERON BETA SERINE;
NATALIZUMAB;
RITUXIMAB;
SB 683699;
UNCLASSIFIED DRUG;
ALPHA4 INTEGRIN;
MONOCLONAL ANTIBODY;
CENTRAL NERVOUS SYSTEM INFECTION;
CLINICAL TRIAL;
DISEASE COURSE;
DRUG DESIGN;
DRUG HALF LIFE;
DRUG POTENCY;
DRUG SAFETY;
EDITORIAL;
HUMAN;
MULTIPLE SCLEROSIS;
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;
SYSTEMIC LUPUS ERYTHEMATOSUS;
ANIMAL;
DRUG DELIVERY SYSTEM;
DRUG EFFECT;
LEUKOCYTE;
METABOLISM;
ORAL DRUG ADMINISTRATION;
TREATMENT OUTCOME;
ADMINISTRATION, ORAL;
ANIMALS;
ANTI-INFLAMMATORY AGENTS;
ANTIBODIES, MONOCLONAL;
DRUG DELIVERY SYSTEMS;
DRUG DESIGN;
HUMANS;
INTEGRIN ALPHA4;
LEUKOCYTES;
MULTIPLE SCLEROSIS, RELAPSING-REMITTING;
TREATMENT OUTCOME;
|
|
EID: 34247860705
PISSN: 14724472
EISSN: None
Source Type: Journal
DOI: None Document Type: Editorial |
|
Times cited : (1)
|
|
References (0)
|
